Search results
Results from the WOW.Com Content Network
A chemotherapy regimen is a regimen for chemotherapy, defining the drugs to be used, their dosage, the frequency and duration of treatments, and other considerations. In modern oncology , many regimens combine several chemotherapy drugs in combination chemotherapy .
A regimen is a plan, or course of action such as a diet, exercise or medical treatment. [1] A low-salt diet is a regimen. A course of penicillin is a regimen, and there are many chemotherapy regimens in the treatment of cancer .
"7+3" in the context of chemotherapy is an acronym for a chemotherapy regimen that is most often used today (as of 2014) as first-line induction therapy (to induce remission) in acute myelogenous leukemia, [1] [2] excluding the acute promyelocytic leukemia form, which is better treated with ATRA and/or arsenic trioxide and requires less chemotherapy (if requires it at all, which is not always ...
This regimen can also be combined with the monoclonal antibody rituximab if the lymphoma is of B cell origin; this combination is called R-CHOP. In 2002, a randomized controlled trial showed a higher complete response rate for R-CHOP vs CHOP in elderly patients with Diffuse Large-B-Cell Lymphoma (76% vs 63%). [ 4 ]
q.1 h, q.1° quaque 1 hora: every 1 hour (can replace 1 with other numbers) q4PM at 4:00 pm (can replace 4 with other numbers) mistaken to mean every 4 hours q.a.d. quaque alternis die: every other day q.a.m. quaque die ante meridiem: every morning (every day before noon) q.d./q.1.d. quaque die: every day
2. Honey. This pantry staple could most likely see you age, move houses, retire, and turn gray — and it would still be good for eating. It literally lasts forever and doesn’t go bad.
MOPP is a combination chemotherapy regimen used to treat Hodgkin lymphoma. The acronym is derived from the component drugs of the regimen: ustargen (also known as mechlorethamine, chlormethine, mustine, nitrogen mustard, or MSD) ncovin (also known as Vincristine or VCR) rocarbazine (also known as Matulane or Natulan)
From January 2008 to December 2012, if you bought shares in companies when Carol B. Tomé joined the board, and sold them when she left, you would have a 4.5 percent return on your investment, compared to a -2.8 percent return from the S&P 500.